6602-33-1

Usage

Uses

Used in Organic Synthesis:
2,6-DIBROMO-3-HYDROXYPYRIDINE is used as a building block in the production of pharmaceuticals, agrochemicals, and other fine chemicals. Its unique structure allows for the synthesis of a wide range of compounds with diverse applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2,6-DIBROMO-3-HYDROXYPYRIDINE is utilized as a reagent in the synthesis of biologically active compounds. Its presence in the molecular structure can contribute to the development of new drugs and pharmaceuticals with potential therapeutic effects.
Used in the Preparation of Heterocyclic Compounds:
2,6-DIBROMO-3-HYDROXYPYRIDINE also serves as a starting material for the preparation of heterocyclic compounds, which are important in various chemical and pharmaceutical applications. Its structural properties make it a valuable precursor for the synthesis of complex heterocyclic systems.
Overall, 2,6-DIBROMO-3-HYDROXYPYRIDINE is a versatile chemical compound with significant applications in organic synthesis, medicinal chemistry, and the preparation of heterocyclic compounds. Its unique structural features make it a valuable building block for the development of new pharmaceuticals and other chemical products.

InChI:InChI=1/C5H3Br2NO/c6-4-2-1-3(9)5(7)8-4/h1-2,9H

Upstream product

• 109-00-2 3-HYDROXYPYRIDINE 
• 137347-01-4 3-ethoxy-2-bromo-6-nitro-pyridine 
• 110-86-1 pyridine 
• 7726-95-6 bromine 

Downstream Products

• 79491-45-5 2,6-dibromo-3-methoxylpyridine 
• 86271-56-9 (E)-2,6-diamino-5-(phenyldiazenyl)pyridin-3-ol 
• 138323-94-1 3-methoxypyridine-2,6-diamine 
• 1355026-47-9 CYM₅₀₁₇₉ 
• 1325189-14-7 1-(7-(4-methylpiperazin-1-yl)furo[2,3-c]pyridin-5-yl)-3-phenylimidazolidin-2-one 
• 1325189-13-6 3-[7-(4-methylpiperazin-1-yl)furo[2,3-c]pyridin-5-yl]-5-phenyl-1,3-oxazolidin-2-one 
• 478148-75-3 2,6-dibromo-4-iodopyridin-3-ol 
• 79491-48-8 2-bromo-5,6-dimethoxy-3-nitropyridine 
• 79491-47-7 2,6-dibromo-5-methoxypyridin-3-amine 
• 79491-49-9 3-amino-5,6-dimethoxypyridine 

Relevant academic research and scientific papers

Inducing Axial Chirality in a Supramolecular Catalyst

A new type of ligand, which is able to form axially chiral, supramolecular complexes was designed using DFT calculations. Two chiral monomers, each featuring a covalently bound chiral auxiliary, form a bidentate phosphine ligand with a twisted, hydrogen-bonded backbone upon coordination to a transition metal center which results in two diastereomeric, tropos complexes. The ratio of the diastereomers in solution is very temperature- and solvent-dependent. Rhodium and platinum complexes were analyzed through a combination of NMR studies, ESI-MS measurements, as well as UV-VIS and circular dichroism spectroscopy. The chiral self-organized ligands were evaluated in the rhodium-catalyzed asymmetric hydrogenation of α-dehydrogenated amino acids and resulted in good conversion and high enantioselectivity. This research opens the way for new ligand designs based on stereocontrol of supramolecular assemblies through stereodirecting chiral centers.

HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists

A knowledge-based library of 2,3-dichlorophenylsulfonyl derivatives of commercially available aryl amines was synthesised and screened as human CCR4 antagonists, in order to identify a suitable hit for the start of a lead-optimisation programme. Hits were required to be more potent than an existing indazole series, have better physicochemical properties (c log P 7.4 116 μg/mL), and be stable to acid and light. The benzimidazol-2-one core was identified as a hit suitable for further investigation. Substitution at N1 with small alkyl groups was tolerated; however, these analogues were inactive in the whole blood assay (pA2 7.4 (2.4), high LE (0.43), and solubility (152 μg/mL). In addition, 38 had human serum albumin binding of around 93% and met all the criteria for progression to lead optimisation.

Phosphoinositide-3-kinase inhibitors: Evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511

Replacement of the piperazine sulfonamide portion of the PI3Kα inhibitor AMG 511 (1) with a range of aliphatic alcohols led to the identification of a truncated gem-dimethylbenzylic alcohol analog, 2-(5-(4-amino-6-methyl-1,3,5-triazin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)amino)pyridin-3-yl)propan-2-ol (7). This compound possessed good in vitro efficacy and pharmacokinetic parameters and demonstrated an EC50 of 239 ng/mL in a mouse liver pharmacodynamic model measuring the inhibition of hepatocyte growth factor (HGF)-induced Akt Ser473 phosphorylation in CD1 nude mice 6 h post-oral dosing.

PESTICIDALLY ACTIVE PYRIDYL- AND PYRIMIDYL- SUBSTITUTED PYRAZOLE DERIVATIVES

Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as insecticides and can be prepared in a manner known per se.

5-HT RECEPTOR MODULATORS

The invention relates to compounds of formula (I), useful for treating disorders mediated by the 5-hydroxytryptamine (serotonin) receptor IB (5-HT1B), e.g. vascular disorders, cancer and CNS disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

PESTICIDALLY ACTIVE PYRIDYL- AND PYRIMIDYL- SUBSTITUTED THIAZOLE DERIVATIVES

Disclosed are pesticidally active pyridyl- and pyrimidyl- substituted thiazole derivatives, processes for their preparation, compositions lcomprising those compounds, and their use for controlling insects.

5-HT RECEPTOR MODULATORS

The invention relates to compounds of formula (I), useful for treating disorders mediated by the 5-hydroxytryptamine (serotonin) receptor 1B (5-HT1B), e.g. vascular disorders, cancer and CNS disorders. The invention also provides methods of treating such disorders, and componnds and compositions etc. for their treatment

Synthesis of the phenylpyridal scaffold as a helical peptide mimetic

Phenylpyridal- and phenyldipyridal-based scaffolds have been designed and synthesized as novel helical peptide mimetics. The synthesis required optimisation and selective alkylation in producing 2,6-functionalized 3-hydroxypyridine derivatives for a convergent scheme. The pyridine analogues were coupled by a series of Suzuki/Stille types cross-coupling reactions. A series of biaryl and ter-aryl substituted heterocycles were produced. The synthetic approach was concise and high yielding allowing large variability at the wanted sidechain attachment points. A number of compounds were synthesised to show the versatility of the strategy.

PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS

The present invention provides novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders relating to aging or stress, diabetes, obesity, neurodegenerative disease, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorder that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. The compounds are of general formula (III) wherein R1, R2, R", X, Y, W, Z1 and Z2 are as defined in the specification.